🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in India / NCT07784725
Recruiting Phase 3

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

NCT07784725 · tracked via the Priya Life Science India tracker
Sponsor
AstraZeneca
Phase
Phase 3
Started
2026-08-19
Last updated
2026-08-25

Condition(s) studied

Obesity or Overweight

Investigational drug(s) / intervention(s)

AZD6234Placebo

AZD6234: IMP injected subcutaneously, once a week. Unit dose strength as per CSP.

Placebo: Placebo matching IMP dose injected subcutaneously, once a week.

Study summary

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Males \& females (inclusive of all gender identities) age ≥18 years * BMI ≥30 kg/m2 OR BMI ≥27 kg/m2 with at least one of the following weight related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, heart failure, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, osteoarthritis of the knee, or stress urinary incontinence * Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation * History of at least one self-reported unsuccessful attempt to lose body weight in their lifetime Exclusion Criteria: * Obesity primarily caused by other endocrine disorders * History of Type 1 or Type 2 Diabetes Mellitus, HbA1c ≥6.5% (48 mmol/mol), and/or treatment with glucose-lowering agent(s) within 3 months prior to Screening * Significant hepatobiliary disease and/or any of the following results at Screening: * ALT ≥ 3.0 × ULN * AST ≥ 3.0 × ULN * TBL \> 1.5 × ULN (except for cases of known Gilbert's Syndrome) * Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation.

Primary outcome measure(s)

Trial sites (212)

FacilityCityRegionStatus
Research Site Dothan Alabama Not Yet Recruiting
Research Site Huntsville Alabama Not Yet Recruiting
Research Site Mesa Arizona Not Yet Recruiting
Research Site Escondido California Not Yet Recruiting
Research Site Clearwater Florida Not Yet Recruiting
Research Site Jacksonville Florida Not Yet Recruiting
Research Site Stockbridge Georgia Not Yet Recruiting
Research Site Champaign Illinois Not Yet Recruiting
Research Site Chicago Illinois Not Yet Recruiting
Research Site Ames Iowa Not Yet Recruiting
Research Site Troy Michigan Not Yet Recruiting
Research Site Jefferson City Missouri Not Yet Recruiting
Research Site Kansas City Missouri Not Yet Recruiting
Research Site Butte Montana Not Yet Recruiting
Research Site Las Vegas Nevada Not Yet Recruiting
Research Site Jersey City New Jersey Not Yet Recruiting
Research Site Cortland New York Not Yet Recruiting
Research Site Statesville North Carolina Not Yet Recruiting
Research Site Fargo North Dakota Not Yet Recruiting
Research Site Columbus Ohio Not Yet Recruiting
Research Site Tulsa Oklahoma Not Yet Recruiting
Research Site Portland Oregon Not Yet Recruiting
Research Site Philadelphia Pennsylvania Not Yet Recruiting
Research Site Smithfield Pennsylvania Not Yet Recruiting
Research Site Kingsport Tennessee Not Yet Recruiting
Research Site Houston Texas Not Yet Recruiting
Research Site San Antonio Texas Not Yet Recruiting
Research Site Sugar Land Texas Not Yet Recruiting
Research Site Waco Texas Not Yet Recruiting
Research Site Salt Lake City Utah Not Yet Recruiting
Research Site Arlington Virginia Not Yet Recruiting
Research Site Renton Washington Withdrawn
Research Site Seattle Washington Not Yet Recruiting
Research Site Buenos Aires Argentina Not Yet Recruiting
Research Site CABA Argentina Not Yet Recruiting
Research Site Ciudad de Buenos Aires Argentina Not Yet Recruiting
Research Site Mendoza Argentina Not Yet Recruiting
Research Site Ramos Mejía Argentina Not Yet Recruiting
Research Site Rosario Argentina Not Yet Recruiting
Research Site San Nicolás Argentina Not Yet Recruiting

+ 172 more sites — see the full list on the official registry below.

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07784725 on ClinicalTrials.gov ↗ ← All trials in India